Skin Cancer Evaluation. Simplified.
A handheld, objective device to assist primary care providers in checking patients for skin cancer in seconds.
DermaSensor™ Features
The Future Standard of Skin Care
- Provides an instant “Further Investigate” or “Monitor” result using DermaSensor’s™ proprietary algorithm
- Technology has a published sensitivity of 94% for detecting skin cancer overall and of 100% for melanoma1
- Wireless, ergonomically designed and easy to hold
- Always on, always ready when needed
Intuitively Designed, Easy to Use
- Intuitive touch-screen interface guides user step by step through the lesion evaluation
- Works in a variety of positions by using the side buttons or hand-held touch-screen
DermaSensor™ is NOT a camera nor a dermatoscope.
DermaSensor™ uses pulses of light and spectroscopy to non-invasively assess lesions’ cellular and sub-cellular characteristics.
Non-Invasive Micron-Level Precision
- Light-emitting tip gently and painlessly touches the surface of the skin to evaluate information below the skin surface
- Tip’s precision optics capture cellular and sub-cellular pathological irregularities throughout a skin lesion as small as 2.5 mm
Always By Your Side
- The handheld unit charges wirelessly in the desktop base
- Secure wireless connectivity allows you to expand use with DermaSensor™ companion software and other applications
- DermaSensor’s™ small size fits on any desk
DermaSensor™ Use
1. Lesion Identification
Physician identifies the lesion of concern on their patient
2. DermaSensor™ Scan
Physician gently touches the small device tip to the lesion, taking instant recordings at different locations of the lesion
3. Photon Scattering
Light reflects and scatters from particles in the cells of the skin tissue back to DermaSensor’s™ spectral sensor
4. Algorithmic Analysis
The proprietary DermaSensor™ algorithm analyzes the reflected photons and provides an immediate “Further Investigate” or “Monitor” result
DermaSensor™ Technology
- DermaSensor’s™ tip reflects and records quick bursts of light off the lesion’s cellular and sub-cellular content.
- The light is analyzed by the built-in computer to provide information to help physicians assess skin lesions (including melanomas, squamous cell carcinomas, and basal cell carcinomas) to aid in a referral decision.
- By examining the difference in light scattering, DermaSensor™ determines if the skin lesion is “Further Investigate” or “Monitor,” an immediate output.
- Elastic Scattering Spectroscopy (ESS) has been validated in 30+ publications on clinical studies. Many studies have shown ESS to provide information that is comparable to histopathologic assessment in the analysis of cellular microscopic structure. 1-4, 15-21
About ESS
DermaSensor™ uses Elastic Scattering Spectroscopy (ESS), a process which evaluates how photons scatter when reflected off of different cellular structures. Malignant lesions have been reported to have different cellular and sub-cellular structures than benign lesions, scattering light differently.
DermaSensor™ for Physicians
Each year ~5,500,000 skin cancers are diagnosed in America making skin cancer more common than all other cancers combined5 6 7. Unfortunately, only 15% of Americans report having ever been screened for skin cancer8 and, even with that low rate, the average wait time for a dermatologist is still 32.3 days9.
While the 5-year survival rate is 98.7% for early-stage localized melanoma, it is only 24.8% for late-stage distant melanoma (metastasized to other organs)10. In addition, the total treatment costs for melanoma in situ is ~$4,648 while Stage IV melanoma is ~$159,808*11.
Effective evaluation of patients with potential skin cancer in primary care is hampered by limited consultation time and limited dermatology training. PCPs will be able to use DermaSensor™ as an adjunctive tool to better assess skin lesions and determine whether additional evaluation is needed.
What is an Adjunctive Tool?
An adjunctive tool, also known as a clinical decision support tool, is not meant to replace clinicians’ decision-making. DermaSensor™ will provide clinicians with additional information about a lesion for them to consider in their referral decision. An adjunctive tool is not a diagnostic, so DermaSensor™ does not definitively determine whether or not cancer is present, specify what type of cancer may be present, nor make any decision for the user.
DermaSensor™ is NOT a camera nor a dermatoscope.
DermaSensor™ uses pulses of light and spectroscopy to non-invasively assess lesions’ cellular and sub-cellular characteristics.
DermaSensor™ Benefits
DermaSensor™ quickly assesses information below the skin surface to give physicians more information and confidence in their decision-making.
DermaSensor™ is designed to improve early detection of skin cancer through its earlier referral to dermatologists and also to reduce the number of unnecessary referrals.
Patients are expected to view DermaSensor™ as a supplemental and valuable addition to the skin care they already receive.
The non-invasive nature of DermaSensor™ is expected to be unintimidating to patients and reassure them that they are receiving high-quality care.
The machine-learning algorithm is derived from thousands of spectral samples of pathologically-verified lesions and is trained by expert data scientists.
Why PCPs Care About Skin Cancer In Their Practice
1 in 5 Americans are diagnosed with skin cancer in their lifetime. 7
Annual cost of treating skin cancers in the U.S. is estimated at $8.1 billion, with an estimated 5.5 million new cases of skin cancer each year.5 6 12
42.7% of patients present with at least one skin condition to their primary care physician. 13
Primary Care Physicians refer as few as 54% of the cancerous lesions they evaluate. 14
As Seen On
